Outcomes and Complications of Lead Removal: Can We Establish a Risk Stratification Schema for a Collaborative and

Hai-Xia Fu1,2, Xin-Miao Huang2,3, L I Zhong2,4

  • 1Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou University, Henan, People's Republic of China.

Insights

Transvenous lead extraction is generally safe and successful. A new risk classification scheme can help determine if lead removal is best done in the electrophysiology lab or operating room.

Area of Science:

  • Cardiology
  • Medical Devices
  • Interventional Electrophysiology

Background:

  • Cardiovascular implantable electronic device removal carries risks.
  • Developing a risk classification for transvenous lead removal is crucial.

Purpose of the Study:

  • To establish a risk classification scheme for transvenous lead removal outcomes.
  • To guide decisions on performing lead extraction in the electrophysiology lab versus the operating room.

Main Methods:

  • Retrospective review of consecutive patients undergoing transvenous lead removal.
  • Analysis of 1,378 leads from 652 patients over an 11-year period.
  • Identification of factors associated with laser-assisted extraction and procedure failure.

Main Results:

  • Lead duration and implantable cardioverter defibrillator (ICD) lead type were linked to laser use and failure.
  • Major complication rate was 1.9%, associated with longer lead duration.
  • High-risk patients (older leads) had significantly more major events than moderate- and low-risk groups.

Conclusions:

  • Transvenous lead removal demonstrates high success rates with low complication rates.
  • A proposed risk stratification scheme categorizes patients into low, moderate, and high risk for extraction.
  • This strategy can inform the optimal setting for lead extraction procedures.
Abstract

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
554
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
545
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.3K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
182